{"product_id":"exelixis-bcg-matrix","title":"Exelixis Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Exelixis’ products land — Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the shifts in market share and growth potential, but the full BCG Matrix gives the quadrant-by-quadrant clarity you need. Purchase the complete report for detailed placements, data-backed recommendations, and ready-to-use Word and Excel files. It’s the shortcut to strategic decisions that actually move the needle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx combo uptake in 1L RCC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabometyx+nivo shows strong share in the fast-growing 1L RCC checkpoint-combo market, which registered double-digit growth in 2024, and uptake is still climbing. The clinical-value story continues to pull through but requires constant promotion and field muscle to sustain prescribing momentum. If Exelixis holds share while the category expands, this franchise can mature into a powerhouse. Invest to defend positioning and keep guideline momentum warm.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx expansion in HCC and other solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-growth tumor types like HCC (905,677 new global cases in 2020 per GLOBOCAN) are seeing rising systemic therapy use, and Cabometyx (cabozantinib; FDA approved in HCC 2019) is already embedded in treatment algorithms. New trial data and real-world evidence broaden indications and line placement, but continuous evidence generation is required. Maintain tight access, low friction, and active KOL engagement to convert uptake into sustainable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS oncology commercial engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS oncology commercial engine delivers scale, reach, and repeatability across a targeted-IO market serving ~1.9 million new US cancer diagnoses in 2024, creating durable pull-through and co-promotion opportunities. It is not won and done: effective payer choreography and pull-through require sustained budget and field intensity. As the market expands the engine compounds results—maintain sales intensity and keep playbooks nimble.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCheckpoint inhibitor partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCheckpoint-inhibitor combos are the hottest segment—PD-(L)1 therapies generated over $50 billion in 2023—and Cabometyx (cabozantinib) synergizes well with IO (cabozantinib+nivolumab approved in RCC 2021), giving Exelixis a meaningful share; however awareness and clear differentiation versus other VEGF–IO combos remain work. Tight, selective partnerships keep Exelixis on the growth curve; more pivotal data, smarter sequencing trials and fewer access barriers are needed.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket: PD-(L)1 \u0026gt;$50B (2023)\u003c\/li\u003e\n\u003cli\u003eCombo edge: Cabometyx+IO approved (RCC, 2021)\u003c\/li\u003e\n\u003cli\u003eStrategy: tight partnerships to capture growth\u003c\/li\u003e\n\u003cli\u003eNeeds: more data, sequencing clarity, improved access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel-driven real-world adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLabel-driven real-world adoption: strong guideline presence plus positive outcomes data drive rapid uptake of Cabometyx, with double-digit YoY commercial growth reported in recent quarters (2024); ongoing clinical education is required to maintain momentum across lines. Sustain registries and HEOR to keep field armed with fresh effectiveness and cost-effectiveness figures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGuideline alignment: drives prescribing\u003c\/li\u003e\n\u003cli\u003eReal-world growth: double-digit YoY (2024)\u003c\/li\u003e\n\u003cli\u003eNeeds: continuous education, registry maintenance\u003c\/li\u003e\n\u003cli\u003eHEOR: prioritize updated cost-effectiveness data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCheckpoint-combo leads 1L RCC: double-digit 2024 growth, PD-(L)1 tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabometyx+nivo holds strong share in the fast-growing 1L RCC checkpoint-combo segment with double-digit category growth in 2024 and ongoing uptake. Cabometyx is embedded in HCC algorithms (905,677 new global HCC cases in 2020) and benefits from PD-(L)1 market tailwinds (PD-(L)1 \u0026gt;$50B in 2023). US oncology scale (~1.9M new cancer diagnoses in 2024) supports durable pull-through if access and data generation continue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFigure\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1L RCC share\u003c\/td\u003e\n\u003ctd\u003eHigh (2024)\u003c\/td\u003e\n\u003ctd\u003eDefend with field spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCategory growth\u003c\/td\u003e\n\u003ctd\u003eDouble-digit (2024)\u003c\/td\u003e\n\u003ctd\u003eUpside if share held\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePD-(L)1 sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$50B (2023)\u003c\/td\u003e\n\u003ctd\u003eCombo tailwinds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCC incidence\u003c\/td\u003e\n\u003ctd\u003e905,677 (2020)\u003c\/td\u003e\n\u003ctd\u003eLarge addressable market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS new cancers\u003c\/td\u003e\n\u003ctd\u003e~1.9M (2024)\u003c\/td\u003e\n\u003ctd\u003eCommercial scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG analysis of Exelixis' portfolio, showing Stars, Cash Cows, Question Marks, and Dogs with investment moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Exelixis BCG Matrix that spots underperformers and growth bets—clean, export-ready for fast C-level decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx in mature RCC lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabometyx in mature RCC lines is an established cash cow with predictable demand and steady prescribing patterns; 2024 net product revenue was about $1.1B, supporting consistent cash flow. Margins have improved as clinical practice cycles into habit, enabling \u0026gt;60% gross margins. Maintain light-touch promotion and smart contracting to preserve revenue while milking the asset without bruising the brand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCometriq niche indications (e.g., MTC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCometriq targets medullary thyroid cancer, which represents about 1–2% of thyroid cancers, keeping the addressable market small but steady in 2024. Limited promotional need and a durable clinical requirement produce reliable, predictable orders, so prioritize supply continuity and clean access. Let it generate cash while optimizing COGS and avoid heavy reinvestment given constrained growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx-US royalties and milestones via partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEx-US royalties and milestone payments from partners are low-growth, high-yield cash cows for Exelixis, historically funding pipeline spend with minimal maintenance costs; in 2024 these partnered streams continued to contribute materially to cash flow. Focus should remain on contract hygiene and demand planning to preserve steady receipts. Don’t fix what isn’t broken.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle management efficiencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLifecycle management efficiencies turn Cabometyx into a cash cow: formulary wins and strengthened distribution reduce patient access friction while mature patient-support programs compress costs; by 2024 Cabometyx already had three major approved indications (RCC, HCC, DTC) and global net product sales above 1 billion USD, letting the machine run leaner as indications age.\u003c\/p\u003e\n\u003cp\u003eTweak, don’t rebuild: incremental label expansions and safety-driven dosing tweaks preserve market share and every basis point of margin funds next-line trials and combos without heavy capital raises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eformulary wins\u003c\/li\u003e\n\u003cli\u003edistribution strength\u003c\/li\u003e\n\u003cli\u003emature patient support\u003c\/li\u003e\n\u003cli\u003e3 indications (RCC, HCC, DTC) by 2024\u003c\/li\u003e\n\u003cli\u003e\u0026gt;$1B global net product sales (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-tail prescriber base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-tail prescriber base sustains stable community oncology use for Exelixis, with light ongoing education, predictable reorder patterns and solid reimbursement that keep the field present without heavy promotional spend; 2024 net product revenue was about $1.3B, reflecting dependable cash flow rather than a growth story. This segment requires modest field effort to maintain share and converts routine prescriptions into reliable margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable demand\u003c\/li\u003e\n\u003cli\u003eLight education burden\u003c\/li\u003e\n\u003cli\u003eSteady reorders\u003c\/li\u003e\n\u003cli\u003eSolid reimbursement\u003c\/li\u003e\n\u003cli\u003eDependable cash, not high growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin oncology cash cow funds R\u0026amp;D while steady royalties sustain cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabometyx is a mature cash cow (2024 net product revenue ~1.1B USD) with \u0026gt;60% gross margins; Cometriq delivers steady niche revenue (medullary thyroid ~1–2% of thyroid cancers); partner royalties\/milestones provide low-growth recurring cash. Preserve margins via light promotion, formulary wins, supply continuity and minimal reinvestment while funding pipeline spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCabometyx\u003c\/td\u003e\n\u003ctd\u003e~1.1B USD; \u0026gt;60% GM\u003c\/td\u003e\n\u003ctd\u003ePrimary cash cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCometriq\u003c\/td\u003e\n\u003ctd\u003eSmall, steady\u003c\/td\u003e\n\u003ctd\u003eNiche cash cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner streams\u003c\/td\u003e\n\u003ctd\u003eMaterial recurring\u003c\/td\u003e\n\u003ctd\u003eSupportive cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eExelixis BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Exelixis BCG Matrix you'll receive after purchase. No watermarks, no demo placeholders—just a fully formatted, analysis-ready report designed by strategy experts. After buying, the final file is delivered instantly to your inbox, ready to edit, print, or present to investors and your team. No surprises, just plug-and-play clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163480568185,"sku":"exelixis-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/exelixis-bcg-matrix.png?v=1762720880","url":"https:\/\/portersfiveforce.com\/products\/exelixis-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}